Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs

European Archives of Psychiatry and Clinical Neuroscience

Volumn 249, Issue SUPPL. 4, 1999, Pages

  Ichikawa, Junji ^a   Meltzer, Herbert Y ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine and serotonin receptors; Negative symptoms and cognitive dysfunction; Schizophrenia; Serotonin dopamine interaction; Typical and atypical antipsychotic drugs

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; AMISULPRIDE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE RECEPTOR; HALOPERIDOL; ILOPERIDONE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN RECEPTOR; SERTINDOLE; ZIPRASIDONE;

AFFECTIVE NEUROSIS; COGNITIVE DEFECT; CONFERENCE PAPER; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; FRONTAL CORTEX; HUMAN; NEGATIVE SYNDROME; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; SEROTONINERGIC NERVE;

EID: 0342980323     PISSN: 09401334     EISSN: None     Source Type: Journal    
DOI: 10.1007/pl00014190     Document Type: Conference Paper

References (113)

1. Abi-Dargham A, Laruelle M, Aghajanian GK (1997) The role of serotonin in the pathophysiology and treatment of schizophrenia. J Neuropsy Clin Neurosci 9:1-17
2. 1A agonist 8-OH-DPAT in the rat. Pharmacol Toxicol 64:3-5
3. 2 receptors: an autoradiographic analysis in rat brain. Brain Res Bull 16:517-525
4. Andersson JL, Nomikos GG, Marcus M, Hertel P, Mathé JM, Svensson TH (1995) Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectively in the mesolimbic dopaminergic system. Naunyn-Schmiedeberg's Arch Pharmacol 352:374-385
5. 1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons. Naunyn-Schmiedeberg's Arch Pharmacol 347:353-362
6. 2 receptor mechanisms contribute to age-related cognitive decline: the effects of quinpirole on memory and motor performance in monkeys. J Neurosci 15:3429-3439
7. Arnt J, Skarsfeldt T (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacol 18:63-101
8. Ashby CR, Wang RY (1996) Pharmacological actions of the atypical antipsychotic drug clozapine: a review. Synapse 24:349-394
9. 1A receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapine. Eur J Pharmacol 334:141-147
10. Breier A (1995) Serotonin, schizophrenia and antipsychotic drug action. Schizophr Res 14:187-202
11. 4 antagonist PNU-101 387G: in vivo effects on mesocortical, mesolimbic, and nigrostriatal dopamine and serotonin release. J Neural Transm 105:749-767
12. Bubser M, Schmidt WJ (1994) Injection of apomorphine into the medial prefrontal cortex of the rat increases haloperidol-induced catalepsy. Biol Psychiatry 36:64-67
13. Buhot MC (1997) Serotonin receptors in cognitive behaviors. Curr Opin Neurobiol 7:243-254
14. 2 receptors? Pharmacol Biochem Behav 36:901-906
15. Davis KL, Kahn RS, Grant K, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148:1474-1486
16. De Deurwaerdère P, Bonhomme N, Lucas G, Le Moal M, Spampinato U (1996) Serotonin enhances striatal dopamine outflow in vivo through dopamine uptake sites. J Neurochem 66:210-215
17. 2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study. Neurosci 91:587-597
18. 2C/2B receptors enhances dopamine release in the rat nucleus accumbens. Neuropharmacol 37:265-272
19. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544
20. 2 receptor-mediated regulation of serotonin extracellular concentration in the raphe nucleus of freely moving rats. J Neurochem 61:772-775
21. Ferré S, Cortes R, Artigas F (1994) Dopaminergic regulation of the serotonergic raphe-striatal pathway: microdialysis studies in freely moving rat. J Neurosci 14:4839-4846
22. Ferré S, Artigas F (1995) Clozapine decreases serotonin extracellular levels in the nucleus accumbens by a dopamine receptor-independent mechanism. Neurosci Lett 187:61-64
23. Gleason SC, Shannon HE (1997) Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacol 129:79-84
24. Gobert A, Rivet J-M, Cistarelli L, Millan MJ (1997) Buspirone enhances duloxetine- and fluoxetine-induced increases in dialysate levels of dopamine and noradrenaline, but not serotonin, in the frontal cortex of freely moving rats. J Neurochem 68:1326-1329
25. 2A receptor activation enhances dialysis levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats. Neuropharmacol 38:315-317
26. Golembiowska K, Wedzony K (1993) Enhancement by ipsapirone of dopamine release in the striatum. Pol J Pharmacol 45:299-308
27. 2 receptor binding in patients with chronic schizophrenia. Psychopharmacol 112:S35-S39
28. Hertel P, Nomikos GG, Iuro M, Svensson TH (1996) Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacol 124:74-86
29. 2-adrenoceptor antagonism. Neuropsychopharmacol 17:44-55
30. Hoffman DC, Donovan H (1995) Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacol 120:128-133
31. Ichikawa J, Meltzer HY (1992) Amperozide, a novel antipsychotic drug, inhibits the ability of d-amphetamine to increase dopamine release in vivo in rat striatum and nucleus accumbens. J Neurochem 58:2285-2291
32. 2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat striatum. Brain Res 698:204-208
33. 1A agonist, inhibits amphetamine-induced dopamine release in rat striatum and nucleus accumbens. Eur J Pharmacol 287:179-184
34. Ichikawa J, Kuroki T, Dai J, Meltzer HY (1998) Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. Eur J Pharmacol 351: 163-171
35. Ichikawa J, O'Laughlin IA, Dai J, Fowler WL, Meltzer HY (1999) Clozapine increased extracellular acetylcholine (ACh-ext) levels in rat medial prefrontal cortex (mPFC) but not striatum (STR) or nucleus accumbens (NAC) in the absence of AChesterase (AChE) inhibition. Soc Neurosci Abstr 25:178.12
36. 1A receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum. J Pharmaeol Exp Ther
37. 1A receptors on antipsychotic drug induced dopamine release in rat striatum and nucleus accumbens. Brain Res
38. Ishii H, Fowler WL, O'Laughlin IA, Meltzer HY, Ichikawa J (1999) M100907, a 5HT2A antagonist, potentiates the ability of R(+)-8-OH-DPAT to increase extracellular dopamine (DA-ext) levels in rat medial prefrontal cortex (mPFC). Soc Neurosci Abstr 25:488.9
39. Iyer RN, Bradberry CW (1996) Serotonin-mediated increase in prefrontal cortex dopamine release: pharmacological characterization. J Pharmacol Exp Ther 277:40-47
40. Jackson BP, Wightman RM (1995) Dynamics of 5-hydroxytryptamine released from dopamine neurons in the caudate putamen of the rat. Brain Res 674:163-166
41. 3H]dopamine via reversal of the dopamine transporter in rat striatum and nucleus accumbens: a comparison with release elicited by potassium, N-methyl-D-aspartic acid, glutamic acid and D-amphetamine. J Pharmacol Exp Ther 262:356-364
42. 2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Pro Natl Acad Sci 95:735-740
43. Jentsch JD, Redmond DE, Elsworth JD, Taylor JR, Youngren KD, Roth RH (1997) Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 277:953-955
44. Jentsch JD, Dazzi L, Chhatwal JP, Verrico CD, Roth RH (1998) Reduced Prefrontal Cortical Dopamine, but not Acetylcholine, Release In Vivo after Repeated, Intermittent Phencyclidine Administration to Rats. Neurosci Lett 258:175-178
45. Kane J, Honigfeld G, Singer J, Meltzer H, the clozaril collaborative study group (1988) Clozapine for the treatment-resistant schizophrenic, A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796
46. Kapur SK, Remington G (1996) Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153:466-476
47. 2 Receptor Occupancy of Clozapine, Risperidone, and Olanzapine in Schizophrenia. Am J Psychiatry 156:286-293
48. 2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 277:968-981
49. Kinon BJ, Lieberman JA (1996) Mechanisms of action of atypical antipsychotic drugs - A critical analysis. Psychopharmacol 124: 2-34
50. Kongsamut S, Roehr JE, Cai J, Hartman HB, Weissensee P, Kerman LL, Tang L, Sandrasagra A (1996) Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur J Pharmacol 317:417-423
51. 2 receptors in rats. Psychopharmacol 140:69-74
52. 1A receptor agonist, inhibits amphetamine-induced serotonin and dopamine release in rat medial prefrontal cortex. Brain Res 743:357-361
53. Kuroki T, Meltzer HY, Ichikawa J (1999) Effect of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 284: 774-781
54. Lee MA, Jayathilake K, Meltzer HY (1999) A comparison of the effect of clozapine with typical neuroleptics on cognitive func-tion in neuroleptic-responsive schizophrenia. Schizophr Res 37: 1-11
55. 2 receptors in schizophrenia: A pet study using [18F]setoperone in neuroleptic-naive patients and normal subjects. Am J Psychiatry 156: 72-78
56. Lipska BK, Jaskiw JE, Braun AR, Weinberger DR (1995) Prefrontal cortical and hippocampal modulation of haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. Biol Psychiatry 38:255-262
57. Loo H, Poirier-Littre MF, Theron M, Rein W, Fleurot O (1997) Amisulpiride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 170:18-22
58. Marder SR (1994) Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825-835
59. 2A receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin. J Neural Transm 104:561-564
60. Matsumoto M, Yoshioka M, Togashi H, Ikeda T, Saito H (1996) Functional regulation by dopamine receptors of serotonin release from the rat hippocampus: in vivo microdialysis study. Naunyn-Schmiedeberg's Arch Pharmacol 353:621-629
61. Maurel-Remy S, Bervoets K, Millan MJ (1995) Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL100907 reflects antagonism of 5-HT2A receptors. Eur J Pharmacol 280:R9-R11
62. i values. J Pharmacol Exp Ther 251: 238-246
63. Meltzer HY, Nash JF (1991) Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 43:587-604
64. Meltzer HY, Gudelsky GA (1992) Dopaminergie and serotonergic effects of clozapine. Implications for a unique clinical profile. Arzneimittel-Forschung 42:268-272
65. Meltzer HY (1995) Atypical antipsychotic drugs. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the Fourth Generation of Progress, pp 1277-1286, Raven Press, New York
66. Meltzer HY, Fatemi SH (1996) The role of serotonin in schizophrenia and the mechanism of action on antipsychotic drugs. In: Kane JM, Moller HJ, Awouters F (eds) Serotonergic Mechanisms in Antipsychotic Treatment, pp 77-107, Marcel Decker, New York
67. Meltzer HY, McGurk SR (1999) The effect of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233-255
68. Meltzer HY, O'Laughlin IA, Dai J, Fowler WL, Ichikawa J (1999) Atypical antipsychotic drugs (APD) but not typical APD increased extracellular acetylcholine (ACh-ext) levels in rat medial prefrontal cortex (mPFC) in the absence of AChesterase (AChE) Inhibition. Soc Neurosci Abstr 25:178.11
69. Mendlin A, Martin FJ, Jacobs BL (1998) Involvement of dopamine D2 receptors in apomorphine-induced facilitation of forebrain serotonin output. Eur J Pharmacol 351:291-298
70. Meneses A, Hong E (1997) A pharmacological analysis of serotonergic receptors: effect of their activation of blockade in learning. Prog Neuropsychopharmacol Biol Psychiatry 21:273-296
71. 1C/2 antagonists as therapeutic agents. Drug News Perspective 5:397-406
72. 2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), hut not 5-HT, release in the frontal cortex in vivo. Neuropharmacol 37:953-955
73. 1A agonist properties: 1. Reciprocal and neurochemical profile in comparison with clozapine and haloperidol. J Pharmacol Exp Ther 286:1341-1355
74. Moghaddam B, Bunney BS (1990) Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 54:1755-1760
75. 1A receptors: a [35S]GTPγS. Eur J Pharmacol 355:245-256
76. Nomikos GG, Iurlo M, Andersson JL, Kimura K, Svensson TH (1994) Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacol 115: 147-156
77. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M (1997) Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385:634-636
78. Pehek EA, Yamamoto BK (1994) Differential effects of locally administered clozapine and haloperidol on dopamine efflux in the rat prefrontal cortex and caudate-putamen. J Neurochem 63: 2118-2124
79. Pehek EA, Bi Y (1997) Ritanserin administration potentiates amphetamine-stimulated dopamine release in the rat prefrontal cortex. Prog Neuro-Psychopharmacol Biol Psychiatry 21: 671-682
80. 2B/C ligands on in vivo dopamine release in the rat prefrontal cortex. Soc Neuroci Abstr 24:48.3 (pp 108)
81. 3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther 280: 73-82
82. Petty F, Kramer G, Moeller M (1994) Does learned helplessness induction by haloperidol involve serotonin mediation? Pharmacol Biochem Behav 48:671-676
83. Prinssen EPM, Ellenbroek BA, Cools AR (1994) Combined antagonism of adrenoceptors and dopamine and 5-HT receptors underlies the atypical profile of clozapine. Eur J Pharmacol 262: 167-170
84. Prinssen EPM, Kleven MS, Koek W (1996) Effects of dopamine antagonists in a two-way active avoidance procedure in rats: interactions with 8-OH-DPAT, ritanserin, and prazosin. Psychopharmacol 128:191-197
85. Protais P, Chagraoui A, Arbaoui J, Mocaer E (1994) Dopamine receptor antagonist properties of S14506, 8-OH-DPAT, raclopride, and clozapine in rodents. EurJ Pharmacol 271:167-177
86. 1a agonist ± 8-OHDPAT modulates basal and stress-induced changes in medial prefrontal cortical dopamine. Synapse 18:218-224
87. 1A receptor activation. Eur J Pharmacol 338:R3-R5
88. 1C receptors. J Pharmacol Exp Ther 260:1361-1365
89. Roth BL, Craigo SC, Choudhary MS, Fredrick AU, Monsma FJ, Shen Y, Meltzer HY, Sibley DR (1994) Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268: 1401-1410
90. Roth BL, Meltzer HY (1995) Serotonin and schizophrenia. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the Fourth Generation of Progress, pp 1215-1227, Raven Press. New York
91. Ruotsalainen S, Sirvio J, Jäkälä P, Puumala T, MacDonald E, Riekkin P (differential effect of three 5-HT receptor antagonists on the performance of rats in attentional and working memory tasks. Eur J Neuropsychopharmacol 7:99-108
92. Santiago M, Matarredona ER, Machado A, Cano J (1998) Influence of serotoninergic drugs on in vivo dopamine extracellular output in rat striatum. J Neurosci Res 52:591-598
93. 1 dopamine receptors in prefrontal cortex: involvement in working memory. Science 251:947-950
94. 1-dopamine receptor in working memory: local injections of dopamine antagonists into the prefrontal cortex of Rhesus monkeys performing an oculomotor delayed-response task. J Neurophysiol 71:515-528
95. 2A receptors in antipsychotic activity. Life Sci 56:2209-2222
96. Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Van Compel P, Lesage AS, DeLoore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacol 124:57-73
97. Seeman P, Lee T, Chau-Wong M, Wong K (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261: 717-719
98. Shipley J (1998) M100907 Phase IIB Trial presented at Hoechst Marion Roussel Conference on M100907, West Palm Beach, Florida, April 1998
99. 2C receptors subtypes in the control of haloperidol-induced release of dopamine in the rat striatum. Soc Neurosci Abstr 24:48.4 (p 108)
100. Tanda G, Caroni E, Frau R, Di Chiara G (1994) Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacol 115:285-288
101. Tanda G, Bassareo V, Di Chiara G (1996) Mianserin markedly and selectively increases extracellular dopamine in the prefrontal cortex as compared to the nucleus accumbens of the rat. Psychopharmacol 123:127-130
102. 2A receptor density abnormality in the cortex of schizophrenic patients studied with PET. Schizophr Res 31:13-17
103. 2 receptor antagonist ketanserin. Eur J Pharmacol 287:201-614
104. Wadenberg ML, Ahlenius S (1991) Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy. J Neural Transm 83:43-53
105. Wadenberg ML (1996) Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat. Neurosci Biobehav Rev 20:325-339
106. 2 receptor blocking agent, ritanserin, in the rat. Eur J Neuropsychopharmacol 6:305-310
107. Wang RY, Liang X (1998) M100907 and clozapine, but not haloperidol or raclopride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons of the rat medial prefrontal cortical slices. Neuropsychopharmacol 19:74-85
108. 1A receptors in the rat prefrontal cortex. Eur J Pharmacol 305:73-78
109. Weinberger DR, Lipska BK (1995) Cortical maldevelopment, antipsychotic drugs, and schizophrenia: a search for common ground. Schizophr Res 16:87-110
110. Wiesel F-A, Nordstrom A-L, Farde L, Eriksson B (1994) An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacol 114:31-38
111. 1 receptors in prefrontal cortex. Nature 376:572-575
112. 2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J Pharmacol Exp Ther 282:699-706
113. Zifa E, Fillion G (1992) 5-Hydroxytryptamine receptors. Pharmacol Rev 44:401-449